Total Solution for SCID and SMA Screening in Laboratories
Total solution for SCID and SMA screening: Delivery, implementation, and maintenance of a validated total solution, comprising hardware, software, reagents, and preventive, corrective, and adaptive maintenance, for multiple screening laboratories. This solution supports the neonatal heel prick screening (NHS) of approximately 170,000 newborns annually in the Netherlands (European and Caribbean), which currently covers 27 rare, hereditary diseases. From 2026, analysis will be performed by three screening laboratories, with RIVM-GZB acting as the reference laboratory. Screening laboratories have used a total solution for SCID since January 2021 and a multiplex solution for SCID and SMA since June 1, 2022; future screening for X-linked agammaglobulinemia (XLA) is possible. The contract is based on a reagent rental principle, where the supplier retains ownership of the equipment.
Never miss a tender again
We send you 3 current matches that fit your company.
Tender documents
- Portal — LOT-0000NON-RESTRICTED-DOCUMENT
- TED HTML — 576741-2026HTML
- TED PDF — 576741-2026PDF
- TED XML — 576741-2026XML
Unlock documents for free
Enter your email address. If you confirm, we will also send you 3 similar tenders.